These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 35235172)

  • 21. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease.
    Oguz F; Demoulin N; Thissen JP; Jadoul M; Morelle J
    Acta Clin Belg; 2022 Aug; 77(4):805-814. PubMed ID: 34404335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uric acid and the cardio-renal effects of SGLT2 inhibitors.
    Bailey CJ
    Diabetes Obes Metab; 2019 Jun; 21(6):1291-1298. PubMed ID: 30762288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of sodium-glucose co-transporter inhibitors on cardiac autonomic function and mortality: no time to die.
    Lim VG; He H; Lachlan T; Ng GA; Kyrou I; Randeva HS; Osman F
    Europace; 2022 Jul; 24(7):1052-1057. PubMed ID: 35080624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiorenal protection of SGLT2 inhibitors-Perspectives from metabolic reprogramming.
    Gao YM; Feng ST; Wen Y; Tang TT; Wang B; Liu BC
    EBioMedicine; 2022 Sep; 83():104215. PubMed ID: 35973390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy.
    Bhardwaj G; Vakani M; Srivastava A; Patel D; Pappachan A; Murumkar P; Shah H; Shah R; Gupta S
    Arch Biochem Biophys; 2021 Oct; 710():108995. PubMed ID: 34289381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations.
    Beal B; Schutte AE; Neuen BL
    Curr Hypertens Rep; 2023 Dec; 25(12):429-435. PubMed ID: 37948021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
    Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
    Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Techniques to Assess the Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Blood Volume in Patients with Diabetic Kidney Disease.
    Vinje V; Bomholt T; Rossing P; Lundby C; Oturai P; Hornum M
    Nephron; 2024; 148(3):137-142. PubMed ID: 37812920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationship between SGLT2 and systemic blood pressure regulation.
    Ahwin P; Martinez D
    Hypertens Res; 2024 Aug; 47(8):2094-2103. PubMed ID: 38783146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations.
    Vrachatis DA; Papathanasiou KA; Iliodromitis KE; Giotaki SG; Kossyvakis C; Raisakis K; Kaoukis A; Lambadiari V; Avramides D; Reimers B; Stefanini GG; Cleman M; Giannopoulos G; Lansky A; Deftereos SG
    Drugs; 2021 Aug; 81(12):1381-1395. PubMed ID: 34297330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
    Andreea MM; Surabhi S; Razvan-Ionut P; Lucia C; Camelia N; Emil T; Tiberiu NI
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
    Neumiller JJ; White JR; Campbell RK
    Drugs; 2010 Mar; 70(4):377-85. PubMed ID: 20205482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: novel insight for better cardio-renal outcomes in chronic kidney disease.
    Masuda T; Nagata D
    Hypertens Res; 2023 May; 46(5):1195-1201. PubMed ID: 36849579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
    Dimova R; Tankova T
    Horm Metab Res; 2021 Feb; 53(2):75-84. PubMed ID: 33202429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.